Cell & Gene The Podcast: Inside BlueRock Therapeutics’ Parkinson’s Disease Trial

Dr. Ahmed Enayetallah, joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the company’s phase I clinical trial for Parkinson’s disease, which continues to show positive trends at 18 months. They cover the important role induced pluripotent stem cells’ (iPSCs) play in the trial, and they also discuss the company’s investigational cell therapy, bemdaneprocel.

Click here to listen.

Related News

Podcasts

Forging the future of cell therapy: Bayer and BlueRock’s unique journey

June 5, 2025
Podcasts

Eye on the Cure Podcast

June 5, 2025
Press Releases

BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease

April 16, 2025
Podcasts

Forging the future of cell therapy: Bayer and BlueRock’s unique journey

June 5, 2025
Podcasts

Eye on the Cure Podcast

June 5, 2025
Press Releases

BlueRock Therapeutics announces publication in Nature of 18-month data from Phase 1 clinical trial for bemdaneprocel, an investigational cell therapy for Parkinson’s disease

April 16, 2025